Palmitoyl pentapeptide-4
pal-KTTKS, palmitoyl-lysyl-threonyl-threonyl-lysyl-serine, palmitoyl pentapeptide-3 (former INCI name), N-palmitoyl-KTTKS
Palmitoyl pentapeptide-4 is a five-amino-acid fragment of type I procollagen (KTTKS) with a 16-carbon palmitic acid tail attached to help it cross the skin's lipid barrier. It is one of the very few cosmetic peptides with a published, placebo-controlled human trial behind it. The effect sizes are modest, and the trial that produced them was run by the company that commercialised the ingredient.
Mechanism
KTTKS is a matrikine: a signalling fragment released when the extracellular matrix is broken down. Katayama and colleagues established in 1993 that the pentapeptide Lys-Thr-Thr-Lys-Ser corresponds to residues 212-216 of the carboxyl-terminal propeptide of type I collagen, and that it is the minimum sequence within the larger 197-241 subfragment needed to stimulate collagen and fibronectin production. In the matrikine model, fragments liberated during matrix turnover act as feedback messengers telling mesenchymal cells to rebuild. No specific cell-surface receptor for KTTKS has ever been identified, which is a genuine gap: the mechanism is defined by what the peptide does downstream, not by a mapped binding site.
The free pentapeptide is far too hydrophilic to cross the stratum corneum in useful amounts. Attaching palmitic acid to the N-terminal lysine converts it into a lipoamino acid conjugate that partitions into the intercellular lipid lamellae, which is the entire reason the palmitoylated form exists. Whether enough intact peptide then reaches living fibroblasts in the dermis to reproduce the concentrations used in cell culture has never been directly demonstrated in human skin. Finished cosmetic products use the peptide at parts-per-million concentrations (the pivotal human trial used 3 ppm), which is orders of magnitude below the levels applied directly to cells in the fibroblast studies. This mismatch is the central unresolved question about the ingredient.
What the research shows
The anchor study is Robinson and colleagues (2005), a 12-week double-blind, placebo-controlled, left-right randomised split-face trial in 93 Caucasian women aged 35-55. One side of the face received a moisturiser; the other received the same moisturiser containing 3 ppm pal-KTTKS. The peptide side showed significant improvement over the placebo control for reduction in wrinkles and fine lines by both quantitative technical image analysis and expert grader image analysis, and the peptide was well tolerated. The split-face design is a real strength (it controls for the enormous inter-individual variation in skin ageing), but the endpoints are appearance-based, there was no histological confirmation, and the work was conducted at Procter & Gamble's Miami Valley Laboratories by the company that commercialised the ingredient.
The only other randomised trial is much weaker, and reading its actual numbers rather than its abstract changes the conclusion. Aruan and colleagues (2023) randomised 21 Indonesian women to acetylhexapeptide-3 cream, palmitoyl pentapeptide-4 cream or placebo (seven per arm) for eight weeks of twice-daily periorbital application. The corneometer, tewameter and cutometer results were all non-significant (p > 0.05). On the Crow's Feet Grading Scale, the palmitoyl pentapeptide-4 arm improved by 0.86 points on both static and dynamic grading, and the placebo arm improved by 0.86 points static and 1.0 point dynamic, that is, by the same amount or more. The paper nonetheless concludes that palmitoyl pentapeptide-4 'demonstrated better results when compared to AHP-3 and placebo'. On the data as published, it did not. This trial provides no support for the ingredient and should not be cited as if it does.
What is missing is more telling than what exists. There is no independent, publicly funded replication of the Robinson trial. There are no biopsy studies in humans demonstrating that topical pal-KTTKS increases dermal collagen density in vivo. Comparisons claiming equivalence to retinol circulate widely in marketing material but do not trace back to any published head-to-head trial with a validated retinoid comparator. Frequently repeated figures such as a '117% increase in collagen I' or a '68% reduction in wrinkle depth' originate from supplier technical literature rather than the peer-reviewed record, and should be treated as promotional claims until someone produces the underlying data.
Evidence assessment
Mixed evidence
One genuine double-blind, placebo-controlled, split-face human trial reached statistical significance on wrinkle endpoints, but it is industry-conducted, uses cosmetic image-grading rather than histology, and the only other randomised trial found the placebo arm improving as much as the peptide arm.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
A pentapeptide from type I procollagen promotes extracellular matrix production Preclinical only
Identified Lys-Thr-Thr-Lys-Ser (residues 212-216) as the minimum sequence needed for potent stimulation of collagen and fibronectin production; the parent subfragment had previously been shown to increase type I collagen, type III collagen and fibronectin in a dose- and time-dependent manner without altering total protein synthesis.
Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin Mixed evidence
Significant improvement versus placebo control for reduction in wrinkles and fine lines by both quantitative technical and expert grader image analysis, with good skin tolerability; subjects also reported significant self-assessed fine line and wrinkle improvement.
Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet Limited evidence
Corneometer, tewameter and cutometer results were all non-significant (p>0.05). Crow's Feet Grading Scale scores fell by 0.86 points (static and dynamic) in the palmitoyl pentapeptide-4 arm and by 0.86 points (static) and 1.0 point (dynamic) in the placebo arm, that is, the placebo arm improved as much or more.
Safety
Palmitoyl pentapeptide-4 has a clean topical safety record as far as it goes. In the Robinson trial it was well tolerated by the skin. In the 2023 crow's feet trial the palmitoyl pentapeptide-4 arm reported no complaints at all, while subjects in both the acetylhexapeptide-3 arm and the placebo arm reported itching, stinging, burning, oiliness or dryness, implicating the vehicle rather than any peptide. The Cosmetic Ingredient Review has a safety assessment of pentapeptides in progress; the document currently posted on the CIR website is a draft watermarked 'Distributed for Comment Only -- Do Not Cite or Quote', so no CIR conclusion can honestly be reported here yet. The important caveats are that the available safety experience covers topical exposure at parts-per-million concentrations only, that there is no toxicology supporting injection or any systemic route, and that the ingredient is almost never used alone. Reported reactions to finished products usually reflect the emulsifiers, preservatives and fragrance around it. Anyone marketing this peptide for injection is operating entirely outside both the evidence base and the safety assessments that exist.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Permitted as a cosmetic ingredient under the UK Cosmetics Regulation (retained EC No 1223/2009). It carries no Annex restriction, prohibition or concentration limit. Efficacy claims are policed under the Cosmetic Products Enforcement Regulations 2013 and must be supportable. It holds no MHRA marketing authorisation as a medicine. |
| United States | Regulated as a cosmetic ingredient, not a drug. Cosmetic ingredients other than colour additives do not require FDA pre-market approval, so 'FDA-registered' or similar claims on skincare packaging carry no regulatory meaning. Any claim that the ingredient alters skin structure or function would reclassify the product as an unapproved drug. There is no approved therapeutic product containing palmitoyl pentapeptide-4. |
| WADA (sport) | Not listed on the WADA Prohibited List. It has no plausible performance-enhancing action and is not a monitored substance. |
Questions
There is one real double-blind placebo-controlled split-face trial (Robinson 2005, n=93) showing significant reduction in fine lines over 12 weeks. So it is not pure marketing. But it is a single industry-conducted trial with appearance-based endpoints, never independently replicated, and the only other randomised trial found the placebo arm improving as much as the peptide arm. It sits above most cosmetic peptides on evidence and well below tretinoin.
That comparison is made constantly in marketing but does not trace back to any published head-to-head trial against a validated retinoid at a therapeutic concentration. Retinoids have decades of independent, biopsy-confirmed evidence for photoageing. Palmitoyl pentapeptide-4 has one good cosmetic trial. They are not in the same evidence class.
That is roughly the concentration the manufacturer's own trial used: 3 ppm in the split-face study where the effect was found. It is worth noting the tension: the fibroblast work that established the collagen-stimulating mechanism applied the peptide directly to cells at vastly higher concentrations. Nobody has demonstrated what fraction of a topical 3 ppm dose reaches dermal fibroblasts intact.
It should not be. Every efficacy trial and every safety consideration for this compound covers topical use at cosmetic concentrations. There is no toxicology, no pharmacokinetics and no human data for any injected route. Vials sold for injection under 'research use only' labelling are outside the evidence base entirely. That phrase is a legal shield permitting sale of unapproved compounds, not a statement about safety or quality.